Showing 2391-2400 of 4166 results for "".
- Samsara Vision to Initiate a US PMA Supplemental Study of the SING IMT, a New-Generation Technology for AMDhttps://modernod.com/news/samsara-vision-to-initiate-a-us-pma-supplemental-study-of-the-sing-imt-a-new-generation-technology-for-amd/2480785/Samsara Vision announced FDA approval to initiate a US-based, PMA supplemental study to evaluate improvements in visual acuity and the safety of its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in people living with late-stage AMD. The CONCERTO trial w
- Recipients of the 2022 Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award Announcedhttps://modernod.com/news/recipients-of-the-2022-prevent-blindness-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award-announced/2480762/Prevent Blindness has announced the recipient of the 2022 Jenny Pomeroy Award for Excellence in Vision and Public Health as VOSH/International (V/I). Additionally, Prevent Blindness has announced the co-recipients of the third annual “Rising Visionary Award” as Marissa K. Sh
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv
- 1-800 Contacts Announces New Company Focused on B2B Vision Technologies and Serviceshttps://modernod.com/news/1-800-contacts-announces-new-company-focused-on-b2b-vision-technologies-and-services/2480662/1-800 Contacts recently announced the formation of a standalone business, Luna Solutions, focused on providing technology and services to third parties in the vision space. The company offers 20 integrated technologies and services–ranging from telehealth platforms for n
- I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United Stateshttps://modernod.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country. E>Eye i
- Centricity Vision Names Todd Pinkney Chief Commercial Officer; Launches New Campaign for Zepto Cataract Surgical Platformhttps://modernod.com/news/centricity-vision-names-todd-pinkney-chief-commercial-officer-launches-new-campaign-for-zepto-cataract-surgical-platform/2480437/Centricity Vision announced that Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the Zepto Platform. "We're confident that Zepto will have a huge impact on the cataract surgery market," Mr. Pinkney said.
- Heru Releases re:Vive 2.0: A Single Wearable Platform with 6 Vision Diagnostic Modalities that Support 5 CPT Codeshttps://modernod.com/news/heru-releases-revive-20-a-single-wearable-platform-with-6-vision-diagnostic-modalities-that-support-5-cpt-codes/2480396/Heru announced it is expanding the capabilities of re:Vive by Heru, the company’s wearable gamified diagnostic solution, to include three new testing modalities: Color Vision CPT 92283, Contrast Sensitivity, and Dark Adaptation CPT 92284. “Since the inception of Heru, our go
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti 1-Day Lenseshttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-1-day-lenses/2479496/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management. Abiliti 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifical
- Refractive Surgery Council Reports Strongest H1 Laser Vision Correction (LVC) Procedure Volume Growth in Nearly a Decadehttps://modernod.com/news/refractive-surgery-council-reports-strongest-h1-laser-vision-correction-lvc-procedure-volume-growth-in-nearly-a-decade/2479384/The Refractive Surgery Council (RSC) reported the strongest first half laser vision correction (LVC) procedure volume growth in nearly a decade. The 82 percent year-over-year growth, fueled by the strong quarter-over-quarter performance, resulted in 231,503 LASIK, SMILE and PRK procedures perform